Active surveillance in stage 1 disease: standard of care independent of risk factors?
Authors:
- 1 March 2020
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Urology
- Vol. 30 (2) , 245-250
Abstract
Purpose of review: Approximately 30% of clinical stage 1 (CS1) nonseminomatous germ cell tumours (NSGCT) and 15–20% of CS1 seminoma relapse without adjuvant treatment. Despite this, the 5-year survival for CS1 is 99%. The purpose of this review is to assess if active surveillance should be standard for all patients with CS1 testis cancer independent of risk factors. Recent findings: Recent data from Princess Margaret Cancer Centre suggest a nonrisk-adapted surveillance approach avoids treatment in ∼70% of patients. Most relapse early at a median time of 7.4 months. The majority of relapses are confined to the retroperitoneum (66%) and only one modality of treatment is required: chemotherapy only in 61% and RPLND only in 73%. Summary: Surveillance is the preferred option and a safe proven strategy for the management of CS1 disease independent of risk factors. The prognosis for CS1 disease is excellent and the decision to offer surveillance or adjuvant treatment needs to highlight the treatment-related morbidity in an otherwise fit and healthy young man.Keywords
This publication has 43 references indexed in Scilit:
- Stage I Testicular Seminoma: A SEER Analysis of Contemporary Adjuvant Radiotherapy TrendsJournal of Urology, 2013
- UK Management Practices in Stage I Seminoma and the Medical Research Council Trial of Imaging and Schedule in Seminoma Testis Managed with SurveillanceClinical Oncology, 2012
- Risk-Adapted Treatment in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: The SWENOTECA Management ProgramJournal of Clinical Oncology, 2009
- The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testisAnnals of Oncology, 2007
- Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 dataThe Lancet Oncology, 2007
- Nerve-Sparing Retroperitoneal LymphadenectomyUrologic Clinics of North America, 2007
- Treating stage I nonseminomatous germ cell tumours with a single cycle of chemotherapyBJU International, 2006
- Second Cancers Among 40 576 Testicular Cancer Patients: Focus on Long-term SurvivorsJNCI: Journal of the National Cancer Institute, 2005
- Handling and Reporting of Biopsy and Surgical Specimens of Testicular CancerEuropean Urology, 2004
- Prognostic Factors for Relapse in Stage I Testicular Seminoma Treated With SurveillanceJournal of Urology, 1997